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Ecteinascidin 743 (ET-743) is a new marine-derived agent with promising activity against a number of solid tumours. In four human
tumour cell lines, the interaction between ET-743 and radiation was investigated in relation to the effects of ET-743 on the cell cycle,
in vitro. Cell survival was measured based on quantitative staining of cellular protein by sulforhodamine B. A 24h treatment with ET-
743 before radiation resulted in a moderate increase in radiosensitivity in three out of four cell lines. Dose enhancement factors X1.8
were observed for concentrations resulting in 52, 46 and 30% cell kill in ECV304, H292 and CAL-27, respectively, whereas in A549
no radiosensitisation was observed (no significant increase in radiosensitivity). According to the combination index analysis, synergism
was observed only in ECV304 and CAL-27 cells. A 24h incubation with ET-743 resulted in a concentration-dependent G2/M block,
which might explain the moderate radiosensitising effects in ECV304 and H292. The lack of radiosensitisation in A549 might be due
to the S phase delay preceding the G2/M block at the moment of radiation, which only occurred in this cell line. In conclusion, ET-743
has moderate cell line-dependent radiosensitising properties; however, only when cytotoxic concentrations of ET-743 are used. In
one of the four cell lines tested, no radiosensitisation was observed.
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Natural products from plants and marine organisms are potential
rich sources of new anticancer agents with possible new
mechanisms of action. Plant-derived agents such as paclitaxel
and docetaxel have already proved to be important drugs for the
treatment of cancer, and an increasing number of substances
originating from marine organisms are being investigated in
preclinical studies and clinical trials. Among the marine anticancer
agents, the ecteinascidins (ETs) merit special consideration. These
colonial tunicates are produced by Ecteinascidia turbinata and
grow preferentially on mangrove roots. Ecteinascidin 743 (ET-743)
(Yondelist) is the most promising compound, based on its
cytotoxicity and its abundance in the tunicate (Jimeno et al, 1996).
Ecteinascidin 743 is a tetrahydroisoquinoline agent (Figure 1)
that binds the minor groove of DNA and forms covalent adducts at
the N2 of guanine (Pommier et al, 1996; Zewail Foote and Hurley,
1999). A unique feature among DNA-interactive agents that occupy
the minor groove is that ET-743 bends DNA towards the major
groove (Zewail Foote and Hurley, 1999; Garcia Nieto et al, 2000).
Also, the sequence specificity of the interaction between ET-743
and DNA is revealed, indicating that DNA duplexes containing
GC-rich sites (50-PuGC-30 and 50-PyGG-30) are putative alkylation
sites. The implications of the study by Moore et al (1998) are that
while units A and B of ET-743 recognise and bind to DNA
duplexes, unit C is directed out of the minor groove and might
directly interact with transcription factors (Pommier et al, 1996).
Ecteinascidin 743 inhibits promotor-specific induction of several
important genes, including p21
WAF 1/CIP 1, c-Jun, c-Fos, MDR1
and others. This compound is a novel, potent and general inhibitor
of activated but not constitutive transcription (Friedman et al,
2002). Ecteinascidin 743 also interferes with the DNA repair
pathway, namely the transcription-coupled nucleotide excision
repair (TC-NER) pathway (Damia et al, 2001; Takebayashi et al,
2001; Zewail Foote et al, 2001), which might be important when
ET-743 is combined with other DNA-damaging agents. Ecteinasci-
din 743 also causes perturbation of the cell cycle with a delay in the
progress through the S phase, finally resulting in a G2/M phase
block (Erba et al, 2001; Li et al, 2001).
In vitro studies with ET-743 have demonstrated activity at
nanomolar concentrations, with a continuous 24h exposure being
more active than a single 1h exposure (Ghielmini et al, 1998;
Izbicka et al, 1998). Ecteinascidin 743 has proven to be a potent
drug against a number of solid tumour cell lines and human
tumour xenografts, including soft-tissue sarcoma, melanoma,
NSCLC, ovarian, breast, prostate and renal cancer (Jimeno et al,
1996; Hendriks et al, 1999; Li et al, 2001).
Ecteinascidin 743 is under active phase II (III) development in
different tumour types. Phase II studies both in the US and Europe
have indicated that ET-743 is an active agent for the treatment of
patients with soft-tissue sarcoma (Le Cesne et al, 2001; Demetri,
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s2002). A pooled analysis of pivotal phase II trials in pretreated
advanced soft-tissue sarcomas demonstrated an objective response
rate of 9.4% and an additional minor response rate of 8.7%, a
1-year survival of 40% and a progression-free survival at 6 months
of 27% (Le Cesne et al, 2001). In addition, early data in ovarian
cancer patients relapsing (X6 months) after platinum–taxane
therapy indicated a 47% response rate with ET-743 in 17 patients
(Parma et al, 2003). The synergistic effect observed in preclinical
models and these clinical data will prompt evaluation of ET-743 in
combination with cisplatin or doxorubicin in ovarian cancer
patients in the near future. Other tumour types in which ET-743 is
presently being explored are breast cancer and endometrial cancer
(Zelek et al, 2000).
In recent years, combined treatments of chemotherapy and
radiotherapy have been investigated extensively in clinical studies,
revealing promising applications for a variety of malignancies such
as NSCLC, head and neck, oesophageal and cervical cancer
(Pignon et al, 2000; Geh, 2002; Kim et al, 2002; Lukka et al,
2002; Rose, 2002). This may result from an improvement in
systemic and local tumour control, and from direct interactions
between cytotoxic agents and radiation, leading to increased
antitumour activity. These interactions may be caused by DNA
repair inhibition, cell cycle redistribution or altered cytokinesis or
apoptosis (Hennequin and Favaudon, 2002). For new chemother-
apeutic agents, it is therefore important to investigate possible
interactions with radiotherapy in vitro, before applying concomi-
tant chemoradiotherapy in the clinic. However, one should keep in
mind that radiosensitising effects do not by definition lead to an
improved therapeutic index. The selectivity of the interaction
between the cytotoxic agents and radiotherapy is a key issue for
improved clinical outcome. Although ET-743 shows a peculiar
pattern of selectivity in cells with different defects in their DNA-
repair pathways (D’Incalci et al, 2002), which suggests normal cells
to be less affected by ET-743, in vivo studies should always be used
to verify an improved therapeutic index.
The aim of the present study was to investigate the interaction
between the novel agent ET-743 and radiotherapy in vitro. Since
cell cycle perturbations frequently play a role in interactions
between chemotherapy and radiation, the effect of ET-743 on the
cell cycle was also investigated.
MATERIALS AND METHODS
Cell lines
Four different human tumour cell lines have been used: ECV304,
an epidermoid bladder cancer cell line; H292, a mucoepidermoid
lung cancer cell line; A549, a squamous lung cancer cell line and
CAL-27, a squamous cell carcinoma cell line of the tongue. ECV304
cells were grown in Medium 199 (Bio Whittaker, Verviers,
Belgium) supplemented with 10% fetal calf serum (Invitrogen,
Merelbeke, Belgium). H292 and A549 cells were cultured in RPMI-
1640 medium, supplemented with 2mM glutamine, 1mM sodium
pyruvate (Invitrogen) and 10% fetal calf serum. CAL-27 cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM) medium,
supplemented with 2mM glutamine and 10% fetal calf serum. No
antibiotics were added to the media. The cultures were maintained
in exponential growth at 371C in a humidified 5% CO2 atmosphere.
Ecteinascidin 743
Ecteinascidin 743 was kindly provided by Dr Glynn T Faircloth,
PharmaMar USA, Inc., Cambridge, MA, USA. Ecteinascidin 743
was dissolved in dimethyl sulphoxide (DMSO) to create a
concentrated stock solution of 660mM and stored in aliquots at
 201C. Aliquots were thawed for each new experiment. Before
use, the stock solution was diluted in phosphate-buffered saline
(PBS: 0.03 M KCl, 1.37 M NaCl, 0.01 M KH2PO4, 0.06 M Na2HPO4)t o
the desired concentrations.
Cell survival experiments
Cells were harvested from exponential phase cultures by trypsi-
nisation, counted and plated at optimal seeding densities in 48-well
plates, to assure exponential growth during the experiments. Cell
densities were about 100cellswell
 1 for all the cell lines tested.
Cells were treated, after a 24h recovery period, in two treatment
schedules: 24h incubation with ET-743 followed by radiation and
24h incubation with ET-743 just after radiation (Cobalt-60 g-rays,
0–8Gy, room temperature). Cells were washed with a drug-free
medium after 24h incubation with the drug, and maintained at
371C. At 7 or 8 days (about six doubling times) after the radiation
treatment, cell survival was determined by the sulforhodamine B
(SRB) assay. Each concentration was tested six times within the
same experiment. All experiments were performed at least three
times.
The SRB test is a suitable test system for in vitro radiosensitivity
testing, which has shown to be comparable in outcome with the
clonogenic assay, when cells are allowed to undergo at least six
doubling times after irradiation (Pauwels et al, 2003). Therefore, in
our experiments, ECV304, H292 and A549 cells were incubated for
7 days and CAL-27 cells for 8 days after radiation, before survival
assessments by the SRB assay. The SRB assay was performed
according to the method of Skehan et al (1990) and Papazisis et al
(1997), with minor modifications. In brief, the culture medium was
aspirated prior to fixating the cells by the addition of 200ml 10%
cold trichloroacetic acid. After 1h incubation at 41C, cells were
washed five times with deionised water. Cells were then stained
with 200ml 0.1% SRB (ICN, Asse, Belgium), dissolved in 1% acetic
acid for at least 15min and washed four times with 1% acetic
acid to remove unbound stain. The plates were left to dry at
room temperature and the bound protein stain was solubilised
with 200ml1 0 m M unbuffered TRIS base (tris(hydroxymethyl)
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Figure 1 Chemical structure of ET-743.
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saminomethane) and transferred onto 96-well plates for reading
the optical density at 540nm (Biorad 550 microplate reader,
Nazareth, Belgium).
Cell cycle experiments
Cells from exponential phase cultures were trypsinised and plated
in 6-well plates. In order to assure exponential growth during the
experiment, seeding densities were 20000 cellswell
 1 for ECV304
and A549, and 25000 cellswell
 1 for H292. Following plating and a
24h recovery period, cells were incubated with different concen-
trations of ET-743 near the IC50. After a 24 or 48h incubation
period, cell cycle analysis was performed immediately, 4 or 24h
later, by flow cytometry.
DNA was stained according to the Vindelov method, after
trypsinisation (Vindelov et al, 1983). In brief, cells were
resuspended in 100ml PBS and after addition of 100ml solution A
(trypsin), the cells were incubated for 20min at room temperature.
Then, 75ml solution B (trypsin inhibitor spermine and ribonu-
clease A) was added and after 10min incubation at room
temperature, 75ml solution C (propidium iodide) was added for
at least 30min at 41C. Samples were analysed in a FACScan flow
cytometer (Becton-Dickinson, San Jose ´, CA, USA).
Data analysis and statistics
Cell survival experiments The survival rates were calculated by:
mean optical density (OD) of treated cells/mean OD of untreated
cells 100%. Radiation dose–survival curves were fitted according
to the linear-quadratic model: survival¼exp( aD-bD
2), using
WinNonlin (Pharsight, Palo Alto, CA, USA). The radiation dose–
survival curves were corrected for the cytotoxic effect of ET-743
alone (the curves were displaced in a vertical direction, so all
dose–survival curves start at 100% survival). From the dose–
survival curves, the ID50 was calculated, which is the radiation dose
causing 50% growth inhibition. A two-sample t-test was used to
investigate significant differences between ID50 values. The results
are expressed as mean7s.d.
Radiosensitisation was expressed by the dose enhancement
factor (DEF): ID50 of the untreated cells/ID50 of the cells treated
with ET-743.
Possible synergism was determined by the calculation of the
combination index (CI) by the Chou and Talalay (1984) equation,
using CalcuSyn (Biosoft, Cambridge, UK), which can also be used
for chemoradiation combinations (Leonard et al, 1996). The CI
takes into account both the potency (IC50 or Dm) and the shape of
the dose–survival curve (m value). The general equation for the
classic isobologram is given by:
CI ¼ð DÞ1=ðDxÞ1 þð DÞ2=ðDxÞ2
where (Dx)1 and (Dx)2 are the doses (or concentrations) for D1 (ET-
743) and D2 (radiation) alone that give x% inhibition, whereas (D)1
and (D)2 are the doses of ET-743 and radiation in combination that
also inhibit x% (i.e. isoeffect).
The (Dx)1 or (Dx)2 (for ET-743 and radiation) are calculated by
the formula:
Dx ¼ Dm½f a=ð1   f aÞ 
1=m
where Dm is the dose required to produce absorbance readings
50% lower than those of nontreated wells (IC50 or ID50), fa is the
fraction affected and m is the slope of the median-effect plot. The
CI values obtained from the classic (mutually exclusive) isobolo-
gram calculations are given. In short, 1.104CI40.90,
0.904CI40.85, 0.854CI40.70 and 0.704CI40.30 indicates a
nearly additive effect, slight synergism, moderate synergism and
synergism, respectively.
Cell cycle experiments Flow cytometric data were analysed using
Cell Quest (Becton Dickinson). A one-way analysis of variance
(ANOVA), followed by a Bonferroni adjustment of the P-value, was
used to investigate the significance of the differences between the
percentages of cells in the different cell cycle phases after treatment
with ET-743 vs the untreated cells.
RESULTS
The four cell lines used in this study were almost equally sensitive
to the cytotoxic effect of ET-743, with mean IC50 values of
1.670.6, 1.170.5, 0.970.4 and 1.570.5nM for ECV304, H292,
CAL-27 and A549, respectively.
Chemoradiation experiments
Figure 2 illustrates dose–response curves of the four cell lines
when treated with the combination of ET-743 and radiation. The
results of cells treated with two different concentrations of ET-743
for 24h before irradiation are shown (other concentrations are also
tested and an overview of the complete results is shown in
Figure 3). Radiation doses ranged from 0 to 8Gy.
In ECV304, H292 and CAL-27, a significant decrease in ID50
values of the ET-743-treated cells compared with the untreated
cells was observed (po0.001). Pretreatment with ET-743 therefore
seemed to increase the radiosensitivity of ECV304, H292 and CAL-
27 cells. On the contrary, no radiosensitising effect was observed in
A549.
An increase in radiosensitivity can be described by the DEF.
This DEF seemed to correlate with the cytotoxic effect of ET-743
alone. In Figure 3, the correlation between the percentage cell kill
caused by ET-743 alone and the DEF is shown for the four cell
lines. In ECV304, H292 and CAL-27, more toxic concentrations of
ET-743 resulted in a higher DEF. In A549, no correlation was
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Figure 2 Survival vs radiation dose curves of four human tumour cell
lines treated with radiation alone vs different concentrations of ET-743 for
24h prior to radiation. (Survival curves were corrected for the cytotoxic
effect of ET-743 itself.) RT¼radiotherapy; Gy¼gray.
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sfound; even toxic concentrations of ET-743 did not result in a
radiosensitising effect (DEF¼1.29 for concentrations around IC50,
without a significant decrease in ID50). In the other three cell lines,
rather toxic concentrations were needed to obtain a clear
radiosensitising effect: DEFs X1.8 were observed for concentra-
tions resulting in 52, 46 and 30% cell kill in ECV304, H292 and
CAL-27, respectively.
To investigate whether these concentrations result in a
synergistic effect between ET-743 and radiation, the CI was
calculated. In ECV304, moderate synergism was observed for
concentrations around IC80, with a CI value of 0.74 (DEF¼2.03).
For concentrations below the IC80, additivity was found. In H292,
the calculation of the CI resulted in a value between 0.90 and 1.10
for concentrations between IC40 and IC80, so only a nearly additive
effect. In CAL-27, concentrations of ET-743 between IC30 and IC50
already gave a CI value of 0.82 (DEF¼1.88), resulting in moderate
synergism. Concentrations around the IC50 resulted in a clear
synergistic effect, with a CI value of 0.65 (DEF¼2.23). In A549
cells, no synergism was observed (CI¼1.08).
In the other treatment schedule, 24h incubation with ET-743
immediately after radiation, no radiosensitising effect was
observed in the four cell lines tested. Figure 4 gives an illustration
of this for ECV304 and H292 cells. The DEF was 1.03 for 0.95nM
ET-743 in ECV304; and 1.07 for 0.75nM ET-743 in H292.
Cell cycle experiments
Treatment with ET-743 caused an accumulation of cells in the G2/
M phase of the cell cycle. This cell cycle effect is concentration
dependent in the three cell lines tested. In ECV304 cells, the
percentage of cells in the G2/M phase increased from 14.270.9%
in the untreated cells, to 31.972.9% after 48h incubation with 2nM
ET-743 and to 37.871.8% after 48h incubation with 3nM ET-743.
In A549 cells, there was an increase from 15.170.8% in untreated
cells, to 43.077.5% after 48h with 0.8nM ET-743 and to
67.473.3% after 48h with 1.8nM ET-743.
In Figure 5 and Table 1, the cell cycle distribution data after
treatment with ET-743 during 24 or 48h, are summarised for
ECV304, H292 and A549 cells. Flow cytometry was performed
immediately, 4 or 24h (not used after 48h incubation) after
treatment. The concentrations used in these cells cycle experi-
ments are close to, or in the range of the observed IC50 values of
the cell lines. In all the three cell lines, an increase in incubation
time (48h instead of 24h) resulted in an increase in the amount of
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Figure 3 Correlation between percentage cell kill caused by ET-743
alone and the DEF in four human tumour cell lines. n¼number of values.
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Figure 5 Cell cycle distribution of ECV304, H292 and A549 after
incubation with ET-743 using different incubation times (24, 48h) and time
intervals (0, 4, 24h). The following concentrations of ET-743 were used:
ECV304: 1.5nM ET-743; H292: 0.75nM ET-743; A549: 1.8nM ET-743.
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scells in the G2/M phase. At 4h after a 24- or 48h-incubation
period, the percentage of cells in G2/M still increased, although less
pronounced in H292. At 24h after a 24h-incubation period, cell
cycle distributions are restored, except in A549 cells. In this cell
line, 24h after a 24h-incubation period, cells were still accumulat-
ing in the G2/M phase. The duration of this G2/M block seemed to
be concentration dependent: 24h after 24h incubation with 1.8nM
ET-743, the percentage of cells in G2/M phase was further
increasing, while for a lower concentration of ET-743 (0.8nM),
the same effect as in ECV304 was observed (data not shown). As
shown in Figure 6, the G2/M block in A549 cells was preceded by a
delay in the S phase after 24h incubation with ET-743.
DISCUSSION
In the current study, we investigated the interaction between ET-
743 and radiation and the effects of ET-743 on the cell cycle, in
vitro. Treatment with ET-743 during 24h before radiation resulted
in a moderate increase in radiosensitivity in three out of four cell
lines. In ECV304, H292 and CAL-27, a significant decrease in ID50
was observed. The decrease in ID50 or the increase in DEF clearly
correlated with the cytotoxic effect of ET-743 alone. Combination
index analysis showed moderate synergism in ECV304 for quite
toxic concentrations around the IC80. In H292 and for lower
concentrations in ECV304, additivity was found. In CAL-27,
synergism was already observed with concentrations around the
IC50, whereas in A549 cells, treatment with ET-743 did not
influence the radiosensitivity of the cell line. Treatment with
ET-743 during 24h after radiation instead of before did not result
in any radiosensitisation.
It has long been known that radiosensitivity changes with the
progression of cells through the cell cycle; while the S phase is
most radioresistant, the G2/M phase is usually considered to be
most radiosensitive (Terasima and Tolmach, 1963; Sinclair and
Morton, 1966). Synchronisation of the cells in G2/M is expected to
elicit the maximum response to radiotherapy. For a few years, this
was also proposed as a rationale for the use of the taxanes in
Table 1 Cell cycle distribution of ECV304, H292 and A549 after
incubation with ET-743 using different incubation times (24, 48h) and time
intervals (0, 4, 24h)
Cell cycle phases (%)
Cell line – conc. ET-743 G1 S G2/M
ECV – 1.5nM
Control 33.174.2 50.675.4 16.372.1
24h 32.675.2 45.676.1 21.773.9
a
24+4h 29.975.5 39.474.7
b 30.874.7
b
24+24h 41.176.1 39.478.6
a 19.472.6
48h 31.875.1 41.473.0
a 26.774.4
b
48+4h 20.773.6
a 43.874.4 35.074.3
b
H292 – 0.75nM
Control 60.874.9 22.873.3 16.071.9
24h 51.171.5
b 26.271.1 22.371.9
a
24+4h 49.773.5
a 25.372.7 24.871.9
a
24+24h 54.272.5 24.272.4 21.270.6
48h 45.674.8
b 24.273.1 29.675.6
b
48+4h 50.171.7
a 22.972.4 26.473.5
b
A549–1.8nM
Control 57.171.3 27.571.2 14.871.0
24h 13.271.7
b 50.975.4
b 35.674.8
b
24+4h 12.273.1
b 37.775.4
a 49.675.1
b
24+24h 9.271.4
b 14.673.1
a 73.671.9
b
48h 10.571.3
b 17.774.8
a 67.473.3
b
48+4h 8.770.9
b 15.772.3
a 72.372.0
b
apo0.05 vs control.
bpo0.005 vs control.
200
0
0 1023
E
v
e
n
t
s
FL2-A
200
0
0 1023
E
v
e
n
t
s
FL2-A
200
0
0 1023
E
v
e
n
t
s
FL2-A
200
0
0 1023
E
v
e
n
t
s
FL2-A
200
0
0 1023
E
v
e
n
t
s
FL2-A
200
0
0 1023
E
v
e
n
t
s
FL2-A
A549 − control
M1
M2
M3
24 + 0 h 
M1
M2
M3
24 + 4 h
M1
M2
M3
24 + 24 h
M1
M2
M3
48 + 0 h
M1
M2
M3
M1
M2
M3 48 + 4 h 
Figure 6 DNA histograms of A549 cells after incubation with 1.8nM ET-743 during a 24 or 48h incubation period and analysed by flow cytometry, 0, 4 or
24h (not used after 48h incubation) later. M1¼G1 phase; M2¼S phase; M3¼G2/M phase.
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scombination with radiotherapy. Pioneering studies indicated
that increased radiosensitivity occurred at the time of the G2/M
block. However, further studies showed a cell line-dependent
radiosensitisation, which was not always associated with the G2/M
block (Hennequin and Favaudon, 2002).
The influence of ET-743 on the cell cycle was investigated in
ECV304, H292 and A549 cells. In all the three cell lines, a
concentration-dependent G2/M block was observed after 24h
incubation with ET-743, which confirmed earlier results (Erba et al,
2001; Li et al, 2001). This G2/M block might explain the moderate
radiosensitising effect in ECV304 and H292. However, since this
G2/M block did not result in a radiosensitising effect in A549, this
cell cycle effect is probably not the only factor for radio-
sensitisation. On the other hand, the lack of radiosensitisation in
A549 cells might be due to the S phase delay at the moment of
radiation, which precedes the G2/M block in this cell line.
Immediately after 24h incubation with ET-743, 50.9% of the cells
are still in the S phase, whereas 35.6% are present in G2/M. After
48h incubation with ET-743 or 24h after 24h- incubation, the G2/
M block is maximal and the percentage of cells in S was reduced to
17.7 and 14.6%, respectively. This might suggest that when A549
cells would be irradiated after 48h incubation with ET-743 or 24h
after a 24h- incubation period, radiosensitisation might occur.
When radiosensitisation indeed is associated with the G2/M block
in the other cell lines, other treatment schedules might also give
more radiosensitisation, such as a 4h interval between a 24h
incubation period and radiation in ECV304.
Cell cycle effects by ET-743 are cell line-dependent, an obser-
vation that has been described previously (Erba et al, 2001; Li et al,
2001). The reason for this cell line dependency still has to
be clarified.
A G2/M block was found in our study, probably caused by
treatment with ET-743. However, care should be taken in assuming
a direct drug-related block because dying cells that are accumulat-
ing in mitosis can also increase the G2/M fraction. However, if it
were only dying cells accumulating in G2/M, instead of a drug-
related block, no radiosensitising effect would be expected.
However, radiosensitisation was seen in our chemoradiation
experiments. To distinguish between dying cells accumulating in
G2/M and a drug-related block, apoptosis vs cell cycle experiments
can be performed.
The in vitro concentrations used in our study (1–2nM)
approximate to peak plasma concentrations observed with 24h
infusion of ET-743 in patients (approximately 2.3nM) (Taamma
et al, 2001). However, whether the observed moderate radio-
sensitising effect will be expected in patients, and especially
whether the therapeutic index will be increased, still has to be
investigated. For this reason, in vivo testing should be considered
for further elucidation of the clinical relevance of the combination
of ET-743 and radiotherapy.
In conclusion, ET-743 has moderate cell line-dependent radio-
sensitising properties. Radiosensitisation might be due to a G2/M
block, and when this would be an important factor, radio-
sensitisation might be more pronounced when cells are irradiated
4–24h after incubation with ET-743, or when the incubation
period is prolonged to 48h. However, further investigation is
necessary to confirm the role of the cell cycle effects caused by ET-
743 in the observed radiosensitisation.
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